LHC Accelerator Research Program

Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes

Retrieved on: 
Wednesday, December 13, 2023
Education, Notability, ASH, Patient, Research, Move, Caregiver, MDS, MD, Cancer, LHC Accelerator Research Program, Society, Nursing, Boston

SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Notable Labs, Ltd. ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that it has donated $60,000 to the Myelodysplastic Syndromes Foundation, Inc. This donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, which was also supported by Notable.

Key Points: 
  • "This funding reflects our deep commitment to developing better treatments for patients with MDS who deserve the fastest possible progress in fighting this severe, life-threatening disease," said Thomas Bock, MD, CEO, Notable Labs.
  • "I am truly excited about partnering with the MDS Foundation in fighting this severe and life-threatening condition.
  • "We are extremely grateful to Notable Labs for their generous sponsorship of our 2023 Move for MDS Community Walks," said Tracey Iraca, Executive Director, MDS Foundation.
  • "The funds raised by the MDS Foundation are used to educate patients and caregivers, as well as to raise awareness of MDS in the community.

Notable Labs Funds Myelodysplastic Syndromes Foundation with $60,000 Grant

Retrieved on: 
Monday, December 11, 2023
Education, Notability, ASH, Disease, Patient, Research, Caregiver, MDS, MD, Cancer, LHC Accelerator Research Program, Society, Pharmaceutical industry, Boston

SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Notable Labs, ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that it has donated $60,000 to the Myelodysplastic Syndrome Foundation, Inc. This donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th American Society of Hematology (ASH) Annual Meeting which Notable Labs also supported here in San Diego, Ca.

Key Points: 
  • Funds will help advance MDS Education, Advocacy and Research
    SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Notable Labs, ("Notable") (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced that it has donated $60,000 to the Myelodysplastic Syndrome Foundation, Inc.
  • This donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th American Society of Hematology (ASH) Annual Meeting which Notable Labs also supported here in San Diego, Ca.
  • Notable Labs served as a National Gold Sponsor of the 2023 "Move for MDS Community Walks to Drive Awareness & Accelerate Research.
  • "We are extremely grateful to Notable Labs for their generous sponsorship of our 2023 Move for MDS walks," said Tracey Iraca, Executive Director, MDS Foundation.

PCAST Working Group, Co-Led by PSMF Founder Joe Kiani, Releases Report on Transforming Patient Safety

Retrieved on: 
Friday, September 8, 2023
Technology, General Health, Public Policy, Government, Foundation, Philanthropy, Hospitals, Science, Cardiology, Diabetes, Health, Health Technology, Public Safety, Research, White House, Federal Government, Software, Advocacy Group Opinion, Artificial Intelligence, Approximation error, Harness, Private sector, Society, Use, Harm, Safety, Health equity, Social, Patient, Information, PSMF, Address, Organization, Patient safety, National Priority, LHC Accelerator Research Program, Develop, Culture, National Patient Safety Foundation, Death, Pharmaceutical industry, Nursing, Medical device, Person, PCAST

Titled “A Transformational Effort on Patient Safety,” the report also outlines the many ways that “patient safety is an urgent national public health issue.” The distinguished PCAST Working Group on Patient Safety is co-led by the founder of the Patient Safety Movement Foundation , Joe Kiani , and Microsoft’s Chief Scientific Officer, Eric Horvitz.

Key Points: 
  • Titled “A Transformational Effort on Patient Safety,” the report also outlines the many ways that “patient safety is an urgent national public health issue.” The distinguished PCAST Working Group on Patient Safety is co-led by the founder of the Patient Safety Movement Foundation , Joe Kiani , and Microsoft’s Chief Scientific Officer, Eric Horvitz.
  • I am optimistic that these recommendations will help fast-track solving this critical problem that destroys so many lives,” said Joe Kiani, co-leader of the PCAST Working Group on Patient Safety.
  • 1.A Appoint a Patient Safety Coordinator Reporting to the President on Efforts to Transform Patient Safety Among All Relevant Government Agencies.
  • Joe Kiani, who founded the Patient Safety Movement Foundation (PSMF) in 2012 and served for many years as its first chair, was appointed to PCAST in September 2021.

5 Lessons Learned Through Surrogacy: 25 Years of Building Families

Retrieved on: 
Tuesday, April 26, 2022
Family, American College of Obstetricians and Gynecologists, Pregnancy, Woman, Research, Medicine, Awareness, Fertility, Blog, Love, LHC Accelerator Research Program, Accelerant, Fourth, Nazca, American College, Parent, Surrogacy, Nursing, Multimedia, ConceiveAbilities, View, Tutoring, Birth control, Gynaecology

In honor of National Infertility Awareness Week , Nazca has five lessons learned through surrogacy that she keeps with her as she continues to lead surrogacy into the future.

Key Points: 
  • In honor of National Infertility Awareness Week , Nazca has five lessons learned through surrogacy that she keeps with her as she continues to lead surrogacy into the future.
  • Medical advancements like single embryo transfer have led to an understanding that surrogacy is the most successful fertility treatment .
  • ConceiveAbilities has learned once exposed to the surrogacy process, an estimated one million women would seriously consider becoming a surrogate.
  • Founder Nazca Fontes is a sought-out thought leader as an innovative force in modern family building for twenty-five years.

The Charcot-Marie-Tooth Association Earns a Perfect Rating From Charity Navigator

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Physician, Efficiency, Charitable organization, Financial health management, 2009 Davis Cup, Charity Navigator, Budget and Accounting Transparency Act of 2014, Charcot–Marie–Tooth disease, CMTA, STAR, Peripheral neuropathy, LHC Accelerator Research Program, Biotechnology, Organic, Patient, Quality of life, Research, CEO, CMT, Medical device, Pharmaceutical industry

The CMTA is only one of 15 health-related charities to earn a perfect score from Charity Navigator, and the only CMT-related organization to earn four stars.

Key Points: 
  • The CMTA is only one of 15 health-related charities to earn a perfect score from Charity Navigator, and the only CMT-related organization to earn four stars.
  • "We are honored to be recognized by Charity Navigator with its top rating," said Amy Gray, CEO of the CMTA.
  • Charities with perfect scores earn the distinction of being recognized among Charity Navigator's "Perfect 100."
  • Less than one percent of the thousands of charities rated by Charity Navigator have earned perfect scores.

CMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Therapy, Clinical trial, Partnership, Neurodegeneration, PMP22, Janssen Pharmaceuticals, Epilepsy, Peripheral neuropathy, Dyskinesia, PAM, SIX Swiss Exchange, Nasdaq, Patient, Glutamate (neurotransmitter), American depositary receipt, Peripheral myelin protein 22, Biomarker, Allosteric regulation, GLOBE, CEO, NAM, Glutamic acid, Histology, Disease, Blepharospasm, ADX71149, Â, LHC Accelerator Research Program, IND, CMT, Research, Drug development, Drug discovery, PTSD, STAR, Glutamate receptor, GABAB, Quality of life, CMTA, Electrophysiology, Protein, Lists of diseases, L-DOPA, Pharmaceutical industry

The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.

Key Points: 
  • The GABAB receptor has previously been shown to be instrumental in controlling the overexpression of Peripheral Myelin Protein-22 (PMP22) in a rat model of CMT1A.
  • Strategic alliances with pharmaceutical partners like Addex Therapeutics support drug development efforts to deliver therapies to CMT patients.
  • We are excited to establish this partnership with Addex Therapeutics as they work to advance their PAMs to treat CMT1A, said CMTAs CEO Amy Gray.
  • Preclinical programs ongoing with Addex include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsons disease and mGlu3 PAM for neurodegenerative disorders.